FDA
-
-
-
-
-
-
-
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
-
-
-
-
-
-
-
Fractyl Health reports weight maintenance data for Revita therapy
-
-
-
-
-
-
-
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
-
-
-
-
-
-
-
Fractyl Health announces proposed public stock offering
-
-
-
-
-
-
-
Fractyl Health (GUTS) Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
-
-
-
-
-
-
-
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
-
-
-
-
-
-
-
Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024
-
325,894 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

